At a moment when policymakers are contemplating measures to reduce drug prices for America’s patients, AAM’s 2021 U.S. Generic and Biosimilar Medicines Savings Report, featuring data from IQVIA, breaks the savings down by state, age, payer, common medical conditions and more.

Because tens of millions of Americans entrust their health to generics and biosimilars, they saved $338 billion in 2020, and nearly $2.4 trillion in the last decade.

**2021 Savings to Medicare:**
$109.6 Billion

**2020 U.S. Generic & Biosimilar Savings:** $338 Billion

93% of Generic Prescriptions Are Filled for $20 or Less

Generics represent 90% of prescriptions filled, yet account for only 18% of prescription drug spending

Generic 10-year savings: nearly $2.4 trillion

Nearly four billion generic and biosimilar prescriptions are dispensed each year

Generics represent only 3% of all health care spending

**Biosimilar Savings:** $7.9 Billion

To date, the FDA has approved 31 biosimilars across 11 molecules. Twenty biosimilars are on the market, with prices that average 30% less than their reference brand biologic. At least six more biosimilars are scheduled to come to market in 2023. This competition has lowered costs for both the reference products and their biosimilars. Since their introduction, biosimilars have been used in more than 121 million days of patient therapy and have supported almost 10 million incremental days of therapy.

**Average Generic Copay:** $6.61
**Average Brand-Name Copay:** $55.82

The amount paid at the pharmacy counter is what matters to patients. High prices can discourage patients from following their prescriptions. Fortunately, 93% of the time, the copay for a generic prescription is under $20.